source
- Moderna and Merck's mRNA melanoma vaccine cuts recurrence risk by 42% in trialA large Phase 2 trial led by Moderna and Merck showed that their personalized mRNA vaccine, intismeran autogene, lowered the chance of melanoma returning by 42% compared with standard therapy. The…
- Merck and Moderna’s cancer vaccine data leak precedes official Phase 3 results releaseResults from the Phase 3 trial of Moderna and Merck’s therapeutic cancer vaccine were made public on Thursday after an earlier leak of the data. The vaccine, called intismeran autogene, is being e…